CN101820881B - 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺 - Google Patents
作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺 Download PDFInfo
- Publication number
- CN101820881B CN101820881B CN2008801077713A CN200880107771A CN101820881B CN 101820881 B CN101820881 B CN 101820881B CN 2008801077713 A CN2008801077713 A CN 2008801077713A CN 200880107771 A CN200880107771 A CN 200880107771A CN 101820881 B CN101820881 B CN 101820881B
- Authority
- CN
- China
- Prior art keywords
- salt
- disease
- compound
- ccr2
- chemical compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UYVNFOLDHCHCNU-UHFFFAOYSA-N COCc1cc(NS(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)c(C(c2c(cc[nH]3)c3ncn2)=O)nc1 Chemical compound COCc1cc(NS(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)c(C(c2c(cc[nH]3)c3ncn2)=O)nc1 UYVNFOLDHCHCNU-UHFFFAOYSA-N 0.000 description 2
- MIGIAWCGEFRREZ-UHFFFAOYSA-N C[n]1c2ncnc(C(c(ncc(Cl)c3)c3NS(c(cc3)cc(C(F)(F)F)c3Cl)(=O)=O)=O)c2cc1 Chemical compound C[n]1c2ncnc(C(c(ncc(Cl)c3)c3NS(c(cc3)cc(C(F)(F)F)c3Cl)(=O)=O)=O)c2cc1 MIGIAWCGEFRREZ-UHFFFAOYSA-N 0.000 description 2
- CGKSZJNKWNBYTJ-UHFFFAOYSA-N Cc1cc(NS(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)c(C(c2c(cc[nH]3)c3nc(C)n2)=O)nc1 Chemical compound Cc1cc(NS(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)c(C(c2c(cc[nH]3)c3nc(C)n2)=O)nc1 CGKSZJNKWNBYTJ-UHFFFAOYSA-N 0.000 description 2
- BDQHYGJZRAKYOB-UHFFFAOYSA-N Cc1cc(NS(c(cc2)cc(Cl)c2Cl)(=O)=O)c(C(c2c(cc[nH]3)c3ncn2)=O)nc1 Chemical compound Cc1cc(NS(c(cc2)cc(Cl)c2Cl)(=O)=O)c(C(c2c(cc[nH]3)c3ncn2)=O)nc1 BDQHYGJZRAKYOB-UHFFFAOYSA-N 0.000 description 2
- YOHOPOGTVHNRMK-UHFFFAOYSA-N Cc1cc(NS(c2cc(C(F)(F)F)c(C)cc2)(=O)=O)c(C(c2c(cc[nH]3)c3ncn2)=O)nc1 Chemical compound Cc1cc(NS(c2cc(C(F)(F)F)c(C)cc2)(=O)=O)c(C(c2c(cc[nH]3)c3ncn2)=O)nc1 YOHOPOGTVHNRMK-UHFFFAOYSA-N 0.000 description 2
- LUUMLYXKTPBTQR-UHFFFAOYSA-N Cc1cnc(C(c2c(cc[nH]3)c3ncn2)=O)c(NS(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)c1 Chemical compound Cc1cnc(C(c2c(cc[nH]3)c3ncn2)=O)c(NS(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)c1 LUUMLYXKTPBTQR-UHFFFAOYSA-N 0.000 description 2
- XMKAUFLYHCMWKI-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1NS(c(cc1)cc(C(F)(F)F)c1Cl)(=O)=O)c1c(cc[nH]2)c2ncn1 Chemical compound O=C(c(ccc(Cl)c1)c1NS(c(cc1)cc(C(F)(F)F)c1Cl)(=O)=O)c1c(cc[nH]2)c2ncn1 XMKAUFLYHCMWKI-UHFFFAOYSA-N 0.000 description 2
- VZMBNJFCSZIJSL-UHFFFAOYSA-N O=C(c1c(cc[nH]2)c2ncn1)c1ncccc1NS(c(cc1)cc(C(F)(F)F)c1Cl)(=O)=O Chemical compound O=C(c1c(cc[nH]2)c2ncn1)c1ncccc1NS(c(cc1)cc(C(F)(F)F)c1Cl)(=O)=O VZMBNJFCSZIJSL-UHFFFAOYSA-N 0.000 description 2
- 0 *#S(c(cc1C(F)(F)F)ccc1Cl)Nc1c(C(c2ncnc3c2nc[n]3)=O)ncc(Cl)c1 Chemical compound *#S(c(cc1C(F)(F)F)ccc1Cl)Nc1c(C(c2ncnc3c2nc[n]3)=O)ncc(Cl)c1 0.000 description 1
- LRVRBKCHVWQAOG-UHFFFAOYSA-N C(C12)C1C1C3C2C1CC3 Chemical compound C(C12)C1C1C3C2C1CC3 LRVRBKCHVWQAOG-UHFFFAOYSA-N 0.000 description 1
- HAWCUEYFSQKISQ-UHFFFAOYSA-N Clc1ccnc2c1nc[nH]2 Chemical compound Clc1ccnc2c1nc[nH]2 HAWCUEYFSQKISQ-UHFFFAOYSA-N 0.000 description 1
- VETRZHKCZGBNNS-UHFFFAOYSA-N NC(c(ncc(Cl)c1)c1N)=O Chemical compound NC(c(ncc(Cl)c1)c1N)=O VETRZHKCZGBNNS-UHFFFAOYSA-N 0.000 description 1
- MIPHUHMTGIOLGI-UHFFFAOYSA-N Nc1c(C#N)ncc(Cl)c1 Chemical compound Nc1c(C#N)ncc(Cl)c1 MIPHUHMTGIOLGI-UHFFFAOYSA-N 0.000 description 1
- QGSSAWJOQFRMTB-UHFFFAOYSA-N O=C(c1c(cc[nH]2)c2ncn1)c(ncc(Cl)c1)c1NS(c(cc1)cc(C(F)(F)F)c1Cl)(=O)=O Chemical compound O=C(c1c(cc[nH]2)c2ncn1)c(ncc(Cl)c1)c1NS(c(cc1)cc(C(F)(F)F)c1Cl)(=O)=O QGSSAWJOQFRMTB-UHFFFAOYSA-N 0.000 description 1
- IFRKGTRUQDWZOR-UHFFFAOYSA-N O=C(c1c2nc[nH]c2ncn1)c(ncc(Cl)c1)c1NS(c(cc1C(F)(F)F)ccc1Cl)(=O)=O Chemical compound O=C(c1c2nc[nH]c2ncn1)c(ncc(Cl)c1)c1NS(c(cc1C(F)(F)F)ccc1Cl)(=O)=O IFRKGTRUQDWZOR-UHFFFAOYSA-N 0.000 description 1
- SSULGNXFUGLULI-UHFFFAOYSA-N O=S(c(cc1C(F)(F)F)ccc1Cl)(Cl)=O Chemical compound O=S(c(cc1C(F)(F)F)ccc1Cl)(Cl)=O SSULGNXFUGLULI-UHFFFAOYSA-N 0.000 description 1
- WOESZFOVOKHIPT-UHFFFAOYSA-N OC(c(ncc(Cl)c1)c1NS(c(cc1C(F)(F)F)ccc1Cl)(=O)=O)=O Chemical compound OC(c(ncc(Cl)c1)c1NS(c(cc1C(F)(F)F)ccc1Cl)(=O)=O)=O WOESZFOVOKHIPT-UHFFFAOYSA-N 0.000 description 1
- VFMIDVIAQMFGGP-UHFFFAOYSA-N [O-][N+](c(cc(cn1)Cl)c1Br)=O Chemical compound [O-][N+](c(cc(cn1)Cl)c1Br)=O VFMIDVIAQMFGGP-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N c1nc2cccnc2[nH]1 Chemical compound c1nc2cccnc2[nH]1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94932807P | 2007-07-12 | 2007-07-12 | |
US60/949328 | 2007-07-12 | ||
PCT/US2008/069813 WO2009009740A1 (en) | 2007-07-12 | 2008-07-11 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101820881A CN101820881A (zh) | 2010-09-01 |
CN101820881B true CN101820881B (zh) | 2013-05-01 |
Family
ID=39852363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801077713A Active CN101820881B (zh) | 2007-07-12 | 2008-07-11 | 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺 |
Country Status (17)
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
WO2009009740A1 (en) | 2007-07-12 | 2009-01-15 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
BR112013015260B1 (pt) | 2010-12-16 | 2020-03-24 | Allergan, Inc. | Derivados de enxofre como moduladores de receptor de quimiocina, composição compreendendo o mesmo e seu uso |
HUE038700T2 (hu) | 2012-03-01 | 2018-11-28 | Allergan Inc | Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk |
US9670190B2 (en) | 2013-03-12 | 2017-06-06 | Allergan, Inc. | Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators |
US20150152080A1 (en) | 2013-12-02 | 2015-06-04 | Allergan, Inc. | Benzothiophene sulfonamides derivatives as chemokine receptor modulators |
US9340509B2 (en) | 2013-12-02 | 2016-05-17 | Chemocentryx, Inc. | CCR6 compounds |
CN104860950A (zh) * | 2014-02-24 | 2015-08-26 | 重庆医药工业研究院有限责任公司 | 一种制备4-氯吡咯[2,3-d]并嘧啶的方法 |
ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
US10682344B2 (en) | 2016-06-03 | 2020-06-16 | Chemocentryx, Inc. | Method of treating liver fibrosis |
US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
AU2017283491B2 (en) * | 2016-06-13 | 2021-06-03 | Chemocentryx, Inc. | Methods of treating pancreatic cancer |
US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
AU2017363299B2 (en) * | 2016-11-23 | 2022-12-22 | Chemocentryx, Inc. | Method of treating focal segmental glomerulosclerosis |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
CN111712242B (zh) | 2017-09-25 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
JP2020536919A (ja) | 2017-10-11 | 2020-12-17 | ケモセントリックス, インコーポレイテッド | Ccr2アンタゴニストによる巣状分節性糸球体硬化症の治療 |
WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
US20190269664A1 (en) * | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
JP7007950B2 (ja) | 2018-03-05 | 2022-01-25 | 東洋鋼鈑株式会社 | パール調光沢フィルム |
EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス,インコーポレイティド | Pd-l1阻害剤としてのインダン |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
AU2021267373A1 (en) | 2020-05-06 | 2022-12-08 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099773A1 (en) * | 2002-05-24 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
WO2004046092A2 (en) * | 2002-11-18 | 2004-06-03 | Chemocentryx | Aryl sulfonamides |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3901855A (en) | 1974-08-07 | 1975-08-26 | Us Air Force | Preparation of polybenzimidazoles |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4227437A (en) | 1977-10-11 | 1980-10-14 | Inloes Thomas L | Frequency detecting apparatus |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4403607A (en) | 1980-05-09 | 1983-09-13 | The Regents Of The University Of California | Compatible internal bone fixation plate |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
JPS61113060A (ja) | 1984-11-08 | 1986-05-30 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
DE3825041A1 (de) | 1988-07-20 | 1990-02-15 | Schering Ag | Pyrido(3,2-e)(1,2,4)triazolo(1,5-a)pyrimidin- 2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwachstumsregulierender und fungizider wirkung |
JPH04364168A (ja) | 1990-08-08 | 1992-12-16 | Taisho Pharmaceut Co Ltd | スルホンアミドピリジン化合物 |
EP0472053B1 (en) | 1990-08-20 | 1998-06-17 | Eisai Co., Ltd. | Sulfonamide derivatives |
JPH06135934A (ja) | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲a2▼阻害剤、抗炎症剤又は抗膵炎剤 |
JPH06145145A (ja) | 1991-12-27 | 1994-05-24 | Ishihara Sangyo Kaisha Ltd | アミノトリフルオロメチルピリジン誘導体又はその塩、それらの製造方法及びそれらを含有するホスホリパーゼa▲2▼阻害剤、抗炎症剤並びに抗膵炎剤 |
US6159686A (en) | 1992-09-14 | 2000-12-12 | Sri International | Up-converting reporters for biological and other assays |
US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
CA2244785C (en) | 1996-02-22 | 2003-12-02 | Tularik, Inc. | Pentafluorobenzenesulfonamides and analogs |
US5780488A (en) | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
ATE360689T1 (de) | 1996-09-10 | 2007-05-15 | Kocher Theodor Inst | Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung |
AR015104A1 (es) | 1996-11-13 | 2001-04-18 | Dowelanco | Compuestos de n-arilsulfilimina sustituidos, utiles como catalizadores en la preparacion de compuestos de n-arilarilsulfonamida; proceso para preparar dichos compuestos y su uso para catalizar dicha preparacion. |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
EP0937711A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
JP4327915B2 (ja) | 1998-03-30 | 2009-09-09 | 株式会社デ・ウエスタン・セラピテクス研究所 | スルフォンアミド誘導体 |
US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
US6380206B1 (en) | 1998-11-23 | 2002-04-30 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives |
JP2000159665A (ja) | 1998-11-27 | 2000-06-13 | Nippon Kayaku Co Ltd | リウマチの予防または治療剤 |
AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
DE60013836T2 (de) | 1999-06-28 | 2006-01-19 | Janssen Pharmaceutica N.V. | Replikationsinhibitoren des respiratorischen synzytialvirus |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
WO2001060369A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
JP2001335714A (ja) | 2000-03-22 | 2001-12-04 | Fuji Photo Film Co Ltd | アゾ色素、その製造方法、インクジェット用インク、インクジェット記録方法 |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
JP2004501913A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Xa因子阻害剤 |
JP3699910B2 (ja) | 2000-10-31 | 2005-09-28 | 株式会社東芝 | データ伝送装置、データ伝送方法及びプログラム |
KR100635703B1 (ko) | 2001-06-07 | 2006-10-17 | 케모센트릭스, 인크. | 세포 이동성 검사 |
US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
WO2003051870A1 (en) | 2001-12-18 | 2003-06-26 | Astrazeneca Ab | Novel compounds |
US7119112B2 (en) | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
US7101883B2 (en) | 2002-03-18 | 2006-09-05 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases |
EP1509477B1 (de) | 2002-05-28 | 2007-05-02 | Schott AG | Vorrichtung zum blankpressen von glaskörpern |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US20070021466A1 (en) | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US20060111351A1 (en) | 2002-11-18 | 2006-05-25 | Solomon Ungashe | Aryl sulfonamides |
AU2003299797A1 (en) | 2002-12-19 | 2004-07-14 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
NZ541234A (en) | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
AU2003290346A1 (en) | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
EP1644008B1 (en) | 2003-05-29 | 2011-12-21 | Abbott Laboratories | Continuous dosing regimen with abt-751 |
US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
GB0322016D0 (en) | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
JP5253815B2 (ja) | 2005-01-14 | 2013-07-31 | ケモセントリックス, インコーポレイテッド | ヘテロアリールスルホンアミドおよびccr2 |
US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
WO2007014008A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
WO2007014054A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
WO2008008394A1 (en) | 2006-07-12 | 2008-01-17 | Transform Pharmaceuticals, Inc. | Tizanidine succinate salt forms and methods of making and using the same |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
WO2008008374A2 (en) * | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
WO2009009740A1 (en) * | 2007-07-12 | 2009-01-15 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
-
2008
- 2008-07-11 WO PCT/US2008/069813 patent/WO2009009740A1/en active Application Filing
- 2008-07-11 AU AU2008275000A patent/AU2008275000B2/en active Active
- 2008-07-11 CA CA2692761A patent/CA2692761C/en active Active
- 2008-07-11 KR KR1020167010696A patent/KR101790908B1/ko active IP Right Grant
- 2008-07-11 KR KR1020107002541A patent/KR101617050B1/ko active IP Right Grant
- 2008-07-11 CN CN2008801077713A patent/CN101820881B/zh active Active
- 2008-07-11 US US12/171,782 patent/US7884110B2/en active Active
- 2008-07-11 KR KR1020187010175A patent/KR101969689B1/ko active IP Right Grant
- 2008-07-11 EP EP08781709A patent/EP2175859B1/en active Active
- 2008-07-11 PL PL08781709T patent/PL2175859T3/pl unknown
- 2008-07-11 JP JP2010516274A patent/JP5306344B2/ja active Active
- 2008-07-11 ES ES08781709T patent/ES2383568T3/es active Active
- 2008-07-11 PT PT08781709T patent/PT2175859E/pt unknown
- 2008-07-11 KR KR1020177030097A patent/KR101849560B1/ko active IP Right Grant
- 2008-07-11 BR BRPI0813695A patent/BRPI0813695B8/pt active IP Right Grant
- 2008-07-11 DK DK08781709.4T patent/DK2175859T3/da active
- 2008-07-11 AT AT08781709T patent/ATE548039T1/de active
-
2010
- 2010-01-12 ZA ZA2010/00212A patent/ZA201000212B/en unknown
- 2010-01-12 IL IL203258A patent/IL203258A/en active IP Right Grant
- 2010-09-24 HK HK10109155.0A patent/HK1142547A1/xx unknown
- 2010-12-22 US US12/976,768 patent/US8546408B2/en active Active
-
2013
- 2013-10-01 US US14/043,602 patent/US9394307B2/en active Active
-
2016
- 2016-06-28 US US15/195,777 patent/US9745312B2/en active Active
-
2017
- 2017-08-04 US US15/669,410 patent/US10208050B2/en active Active
-
2019
- 2019-01-11 US US16/246,181 patent/US10899765B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099773A1 (en) * | 2002-05-24 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
WO2004046092A2 (en) * | 2002-11-18 | 2004-06-03 | Chemocentryx | Aryl sulfonamides |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101820881B (zh) | 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺 | |
CN101511800B (zh) | 三唑基苯基苯磺酰胺 | |
JP6322325B2 (ja) | Cc9アンタゴニストとしてのピラゾール−1−イルベンゼンスルホンアミド | |
KR20150133172A (ko) | Mk2 억제제 및 이의 용도 | |
JP2022532034A (ja) | Rafキナーゼの阻害剤 | |
CN107708699A (zh) | 肿瘤生物标志物及其应用 | |
CN116888125B (zh) | Tyk2抑制剂及其用途 | |
TW201625610A (zh) | 萘啶二酮(naphthyridinedione)衍生物 | |
CN110305125A (zh) | 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 | |
CN116768886A (zh) | N-(4-(1H-吡咯并[2,3-b]吡啶-5-基)苯基)酰胺衍生物及制备与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |